VX20-121-102:A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects with Cystic Fibrosis Who are Heterozygous for F508del and a Minimal Function Mutation